Research Article

Deciphering the Key Pharmacological Pathways and Targets of Yisui Qinghuang Powder That Acts on Myelodysplastic Syndromes Using a Network Pharmacology-Based Strategy

Zijian Han (1, 2), Luping Song (3), Kele Qi (2, 4), Yang Ding (2, 5), Mingjun Wei (6), and Yongcun Jia (7)

1 People’s Hospital of Ningxia Hui Autonomous Region, Department of Medical Engineering, Yinchuan 750002, China
2 ST he First Affiliated Hospital of Northwest University for Nationalities, Yinchuan 750002, China
3 People’s Hospital of Ningxia Hui Autonomous Region, Department of Clinical Pharmacy, Changsha 410600, China
4 People’s Hospital of Ningxia Hui Autonomous Region, Department of Emergency Medicine, Yinchuan 750002, China
5 People’s Hospital of Ningxia Hui Autonomous Region, Department of Burn and Plastic Surgery, Yinchuan 750002, China
6 South China University of Technology, Graduate School, Guangzhou, 510006, China
7 People’s Hospital of Ningxia Hui Autonomous Region, Department of Clinical Laboratory, Yinchuan 750002, China

Correspondence should be addressed to Yongcun Jia; jyongcun@163.com

Received 9 August 2020; Revised 10 November 2020; Accepted 27 November 2020; Published 8 December 2020

Academic Editor: Zhiqian Zhang

Copyright © 2020 Zijian Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Yisui Qinghuang powder (YSQHP) is an effective traditional Chinese medicinal formulation used for the treatment of myelodysplastic syndromes (MDS). However, its pharmacological mechanism of action is unclear. Materials and Methods. In this study, the active compounds of YSQHP were screened using the traditional Chinese medicine systems pharmacology (TCMSP) and HerDing databases, and the putative target genes of YSQHP were predicted using the STITCH and DrugBank databases. Then, we further screened the correlative biotargets of YSQHP and MDS. Finally, the compound-target-disease (C-T-D) network was conducted using Cytoscape, while GO and KEGG analyses were conducted using R software. Furthermore, DDI-CPI, a web molecular docking analysis tool, was used to verify potential targets and pathways. Finally, binding site analysis was performed to identify core targets using MOE software. Results. Our results identified 19 active compounds and 273 putative target genes of YSQHP. The findings of the C-T-D network revealed that Rb1, CASP3, BCL2, and MAPK3 showed the most number of interactions, whereas indirubin, tryptanthrin, G-Rg1, G-Rb1, and G-Rh2 showed the most number of potential targets. The GO analysis showed that 17 proteins were related with STPK activity, PUP ligase binding, and kinase regulator activity. The KEGG analysis showed that PI3K/AKT, apoptosis, and the p53 pathways were the main pathways involved. DDI-CPI identified the top 25 proteins related with PI3K/AKT, apoptosis, and the p53 pathways. CASP8, GSK3B, PRKCA, and VEGFR2 were identified as the correlative biotargets of DDI-CPI and PPI, and their binding sites were found to be indirubin, G-Rh2, and G-Rf. Conclusion. Taken together, our results revealed that YSQHP likely exerts its antitumor effects by binding to CASP8, GSK3B, PRKCA, and VEGFR2 and by regulating the apoptosis, p53, and PI3K/AKT pathways.

1. Introduction

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological disorders characterized by bone marrow (BM) dysplasia, abnormal myeloid cell differentiation, peripheral blood cytopenia, and an increased risk of leukemic transformation [1]. MDS results in poor clinical outcomes, and the duration of patient survival is less than 2 years for the higher risk subtypes [2]. Immunomodulatory drugs (e.g., lenalidomide), hypomethylating agents (e.g., 5-azacytidine and decitabine), and stem cell transplantation are currently approved methods of treatment for MDS [3–5].
but are limited due to chemoresistance and adverse effects of the drugs. Therefore, there is an imperative need to develop novel therapeutic strategies against MDS.

Traditional Chinese medicine (TCM) has been used to treat various illnesses for thousands of years and is associated with fewer toxic effects compared with pharmacological drugs [6, 7]. Yisui Qinghuang powder (YSQHP), a TCM formulation used to treat MDS, consists of indigo naturalis (qingdai), red ginseng (hongshen), and realgar (xionghuang) [8, 9], a mineral consisting of arsenic sulfide (As$_2$S$_3$) and arsenic trioxide (As$_2$O$_3$). As$_2$S$_3$ is an insoluble compound, while As$_2$O$_3$ is a soluble therapeutically active compound [10]. Although the therapeutic effects of YSQHP are encouraging, its pharmacological mechanisms of action are still unknown.

Network pharmacology integrates systems biology with polypharmacology and is a suitable approach to characterize complex TCM formulations and identify their multiple targets and mechanisms of action [7, 11]. We identified the bioactive compounds of YSQHP using the TCMSP [12] and HerDing databases [13] and established the network of these compounds, their putative targets, and diseases. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) database analyses were then used to elucidate multiple targets and pathways affected by YSQHP in MDS. The signaling pathways elucidated through network pharmacology were validated using DDI-CPI, a web tool based on AutoDock Vina [14] and MOE software (strategies used are shown in Figure 1).

2. Methods

2.1. Identification of Bioactive Compounds. The constituents of YSQHP were screened for using the traditional Chinese medicine systems pharmacology (TCMSP) (https://tcmspw.com/tcmsp.php) which is a unique systems pharmacology platform of Chinese herbal medicines that captures the relationships between drugs, targets, and diseases. And, HerDing (http://210.107.182.73/TCMIDWebService/herdingDemo.jsp) database is a search engine that recommends herbs to treat diseases using genes and chemicals by integrating existing several databases and a text mining approach.

The pharmacokinetic interactions of the compounds were identified using ADME (absorption, distribution, metabolism, and elimination), and the active compounds of YSQHP were screened for two drug-likeness indices OB (oral bioavailability) value of ≥30% and DL (drug-likeness) value of ≥0.18 for eliminating the ineffective compounds in herbs. Then, the active compounds omitted from the supplementary part were excavated by reading the literature.

2.2. Target Prediction of the Active Compounds. The key targets of As$_2$O$_3$ were identified using the STITCH database (http://stitch.embl.de/) [15] and the DrugBank database (https://www.drugbank.ca/) [16]. Then, information on the active compounds omitted from the supplementary section was extracted by scanning the relevant literature, especially the literature on ginsenosides and the secondary metabolites of ginsenosides. We collected information using the TCMSP and HerDing databases, and the names and chemical structures of the 19 compounds were obtained. All information on the compounds was standardized based on “Canonical SMILES,” which is based on the PubChem database (https://pubchem.ncbi.nlm.nih.gov/).

2.3. Screening of the MDS-Related Targets. The potential therapeutic targets of MDS were screened for from the GeneCards (https://www.genecards.org/) and Online Mendelian Inheritance in Man (OMIM) (http://www.omim.org/) databases using the keyword, myelodysplasia syndrome. After duplicate data were removed, the proteins obtained from both databases were pooled using R software and converted into UniProt IDs.

2.4. Network Construction. The relationship between the active ingredients of YSQHP and the predicted targets and active compounds were visualized by constructing the compound-target-disease (C-T-D) network using Cytoscape (v.3.6.1). The target-target (T-T) network between YSQHP and MDS was constructed using the STRING database (https://string-db.org/) based on a minimum required interaction score of 0.900, and it was visualized using Cytoscape.

2.5. GO and KEGG Pathway Analyses. The signaling pathways associated with the therapeutic targets of MDS were then identified using DAVID (Database Visualization and Integrated Discovery software, http://david.abcc.ncifcrf.gov). The genes were functionally annotated through the GO analysis, and significantly enriched terms with a P value <0.5 and FDR <0.5 were screened for. The KEGG (http://www.genome.jp/kegg/) database was used to identify enriched pathways, and data were analyzed and displayed using the GO plot package of R software (v.3.6.1). To further elucidate the mechanism underlying the therapeutic effect of YSQHP against MDS, selected targets were annotated for the apoptosis, p53, and PI3K/AKT signaling pathways (KEGG number: map04210, map04115, and map04151) to identify the interacting genes, and the network was drawn using the KEGG parser.

2.6. Molecular Docking Simulation. Drug-drug interactions were predicted via chemical-protein interactome or using DDI-CPI (https://cpi.bio-x.cn/ddi/) to simulate molecule docking and predict drugs with similar structure. Eleven effective compounds in YSQHP (arsenic trioxide was not identified in the database; 3 compounds were identified in indigo naturalis; and 8 compounds were identified in red ginseng) were identified, and the structure of these 11 compounds was uploaded to the website for docking. Based on the optimistic model of the data mining results of this website, a docking score that was less than or equal to −8.4 was considered to indicate a potential interaction with the protein. To understand the frequency of the occurrence and
the molecular functions of the potential targets, keywords, such as apoptosis, p53, and PI3K/AKT, were used to classify the functions of the proteins. Using the frequency of potential targets in the list, the top 25 proteins were selected and were used in the chemical-protein interactome (CPI) analysis. The molecular docking of indirubin, G-Rh2, G-Rf to GSK3B, CASP8, PRKCA, and VEGFR2 was verified using MOE software (v.2019.0102).

3. Results

A total of 11 compounds were identified in red ginseng: 9 compounds from TCMSP and 8 compounds from HerDing. Furthermore, 8 compounds of indigo naturalis, 8 compounds from TCMSP, and 3 compounds from HerDing were also identified (see Table 1 for details).
A total of 273 known targets of YSQHP were extracted from the TCMSP, HerDing, and STITCH databases, and 2,014 MDS-related genes were obtained from the OMIM and GeneCards databases. The Venn plot revealed that 129 MDS-related genes were also targeted by YSQHP (Figure 2(a)). The C-T-D network comprised 150 nodes and 339 edges (Figure 2(b)). Among the MDS-related genes, Rb1, CASP3, BCL2, and MAPK3 showed the most number of interactions, whereas indirubin, tryptanthrin, G-Rg1, G-Rb1, and G-Rh2 showed the most number of potential targets.

The T-T network comprised 129 nodes and 545 edges, with an average node degree of 8.45 and an average local clustering coefficient of 0.459 (Figure 3(a)). P53, AKT1, STAT3, MAPK1, and MAPK3 showed the most number of interactions, whereas indirubin, tryptanthrin, G-Rg1, G-Rb1, and G-Rh2 showed the most number of potential targets.

The GO analysis of the 129 overlapping targets showed that protein serine/threonine kinase activity, ubiquitin-like protein ligase binding, kinase regulator activity, ubiquitin protein ligase binding, and DNA-binding transcription activator activity (RNA polymerase II-specific) were the top 5 enriched functions. In addition, 17 proteins were associated with protein serine/threonine kinase activity with a gene ratio of 0.132, while 16 proteins were associated with ubiquitin-like protein ligase binding function (Figure 3(c)). Thus, YSQHP compounds could potentially target these proteins to regulate kinase activity, in particular serine/threonine and ubiquitination.

The top 5 significantly enriched pathways among the 129 overlapping genes were PI3K/ AKT (33 proteins), apoptosis (26 proteins), cellular senescence (24 proteins), and cell cycle and the MAPK signaling pathways (15 proteins), as shown by the KEGG analysis (Figure 3(d)). The p53 pathway ranked sixth with 18 proteins and is known to play a key role in both the cellular senescence and cell cycle pathways. Since p53 was also a hub protein in the PPI network, we surmised that the p53 pathway is targeted by YSQHP in MDS. The top 25 proteins were identified based on the docking score and the target functions (keywords: p53, apoptosis, and AKT) (Figure 4(a)). Furthermore, CDK2, EHMT1, EHMT2, KDM1A, VCP, CSNK2A1, CSNK2A2, MAPK9, and PRKCA were found to be associated with p53. CASP8, GSK3B, HCK, NGAL, PIM1, PIR, and PRKCA are likely to be involved in apoptosis. In addition, AKT2, FGFR2, LYN, PRKCB, PRKCG, CSF1R, EGFR, PTK2B, and VEGFR2 were associated with PI3K/AKT. CSNK2A1, CSNK2A2, MAPK9, and PRKCA were associated with both p53 and apoptosis, whereas AKT2, FGFR2, LYN, PRKCB, and PRKCG were common to both apoptosis and PI3/AKT. The indigo naturalis compounds had a high molecular docking score (<−8.4) with most of the top 25 targets, while indirubin produced the highest score of −11.4, which corresponds to its interaction with all but NGAL. In red ginseng, G-Rd, G-Rf, and G-Rh2 showed relatively higher scores, compared with G-Rg1, G-Rb1, and G-Re (Figure 4(b)) (see Table 2 for details).

| Crude drugs              | Active ingredient (abbreviation)             |
|--------------------------|---------------------------------------------|
| Red ginseng (Hongshen)   | Ginsenosides Rg1 (G-Rg1)                     |
|                          | Ginsenosides Rf (G-Rf)                      |
|                          | Ginsenosides Re (G-Re)                      |
|                          | Ginsenosides Rd (G-Rd)                      |
|                          | Ginsenosides Re (G-Rc)                      |
|                          | Ginsenosides Rb1 (G-Rb1)                    |
|                          | Ginsenosides Rb2 (G-Rb2)                    |
|                          | Ginsenosides Rh2 (G-Rh2)                    |
|                          | Di-n-octyl phthalate (DNOP)                  |
|                          | Beta-elemene (β-elemene)                     |
|                          | Beta-sitosterol (β-sitosterol)               |
|                          | Indirubin                                    |
|                          | Indigo                                       |
|                          | Isoindigo                                    |
|                          | Isovitexin                                   |
| Indigo naturalis (Qingdai)| Tryptanthrin                                 |
|                          | 6-(3-Oxindolin-2-ylidene) indolo[2, 1-b] quinazolin-12-one (qingdainone) |
|                          | 10h-Indolo, [3, 8-b], quinoline (quinoline)  |
|                          | Beta-sitosterol (β-sitosterol)               |
| Realgar (Xionghuang)     | Arsenic trioxide (As2O3)                     |

**Table 1:** Crude drugs and active components in YSQHP.
Figure 2: Screening of potential targets and the compound-target-disease network. (a) All MDS targets (2,014) obtained from GeneCards and OMIM, the 273 targets of YSQHP obtained using the TCMSP and HerDing databases, and their intersection (129 genes). Blue: the 2,014 targets related to MDS (disease); red: the 273 targets of YSQHP (drug); dark red: the 129 overlapping targets between MDS and YSQHP. (b) compound-target-disease (C-T-D) network of the 129 overlapping targets of MDS and 19 YSQHP compounds (11 from red ginseng and 8 from indigo naturalis and realgar). Red diamond: YSQHP (drug); blue circles: effective molecules in the drug (19 ingredients); purple square: MDS (disease); green dots: disease-related targets (129 genes); black lines: network relationships.

Figure 3: Continued.
The pentasaccharide of G-Rh2 interacts with Lys320 and Asp363 of CASP8 (S: -7.3252 and E refine: -40.5020) and that of G-Rf may bind to Asp133 and Asp200 of GSK3B (S: -7.3067 and E refine: -22.5884). Indirubin showed potential binding with Leu840, Val848, Cys1045, and Val899 of VEGFR2 (S: -6.7621 and E refine: -27.5642) and is likely to bind to GSK3B via arene-H interaction with Val70, Ile62, and Val135 (S: -6.4944 and E refine: -33.7944). PRKCA may also be a potential target of indirubin and interact through Lys368 and Asp481 (S: -5.5508 and E refine: -27.0008).

4. Discussion

Network pharmacology is a novel field that integrates pharmacology, biochemistry, genomics, and bioinformatics [7]. It is an effective strategy to visualize and analyze complex interactive data on herbs, compounds, targets, and diseases based on computer modeling analysis and target prediction methods [11] and is especially suitable for characterizing TCM formulations. Furthermore, molecular docking is a powerful method used to predict the binding force between the drug compounds and their putative targets.
Fibroblast growth factor receptor 2
Casein kinase II subunit alpha
Lysine-specific histone demethylase 1A
Transitional endoplasmic reticulum ATPase
Protein kinase C iota type
Tyrosine-protein kinase Lyn
Vascular endothelial growth factor receptor
Casein kinase II subunit alpha
Caspase-8
Glycogen synthase kinase-3 beta
Macrophage colony-stimulating factor 1 receptor
Mitogen-activated protein kinase 9
Protein kinase C beta type
Epidermal growth factor receptor
Neutrophil gelatinase-associated lipocalin
Protein kinase C alpha type
Protein-tyrosine kinase 2-beta
Cyclin-dependent kinase 2
Histone-lysine N-methyltransferase EHMT1
Histone-lysine N-methyltransferase EHMT2
Pirin
Protein kinase C theta type
RAC-beta serine/threonine-protein kinase
Serine/threonine-protein kinase pim-1
Tyrosine-protein kinase HCK

| Protein name                                      | Abbreviation |
|--------------------------------------------------|--------------|
| Fibroblast growth factor receptor 2              | FGFR2        |
| Casein kinase II subunit alpha                    | CSNK2A2      |
| Lysine-specific histone demethylase 1A           | KDM1A        |
| Transitional endoplasmic reticulum ATPase        | VCP          |
| Protein kinase C iota type                        | PRKCI        |
| Tyrosine-protein kinase Lyn                       | LYN          |
| Vascular endothelial growth factor receptor 2    | VEGFR2       |
| Casein kinase II subunit alpha                    | CSNK2A1      |
| Caspase-8                                         | CASP8        |
| Glycogen synthase kinase-3 beta                  | GSK3B        |
| Macrophage colony-stimulating factor 1 receptor  | CSF1R        |
| Mitogen-activated protein kinase 9               | MAPK9        |
| Protein kinase C beta type                        | PRKCB        |
| Epidermal growth factor receptor                 | EGFR         |
| Neutrophil gelatinase-associated lipocalin       | NGAL         |
| Protein kinase C alpha type                       | PRKCA        |
| Protein-tyrosine kinase 2-beta                   | PTK2B        |
| Cyclin-dependent kinase 2                        | CDK2         |
| Histone-lysine N-methyltransferase EHMT1          | EHMT1        |
| Histone-lysine N-methyltransferase EHMT2          | EHMT2        |
| Pirin                                            | PIR          |
| Protein kinase C theta type                       | PRKCQ        |
| RAC-beta serine/threonine-protein kinase         | AKT2         |
| Serine/threonine-protein kinase pim-1             | PIM1         |
| Tyrosine-protein kinase HCK                       | HCK          |

**Figure 4:** Drug-drug interactions via chemical-protein interactome (DDI-CPI) analysis dock score of the compounds in YSQHP. (a) Top 25 targets of YSQHP in the drug-drug interaction (DDI) obtained via chemical-protein interactome (CPI) analysis. The target proteins are represented using different colors. The number represents the number of active components that interact with the target. (b) Heatmap showing the docking scores of 3 compounds in indigo naturalis and 8 compounds in red ginseng to the top 25 targets. * Apoptosis: proteins directly involved in the apoptosis pathway; related to apoptosis: proteins involved in the apoptosis pathway and other pathways.
Figure 5: Continued.
based on the spatial structure of the drug and ligand. PPI-CPI is a web tool based on AutoDock Vina that can analyze putative PK/PD proteins and decipher the potential mechanisms of the DDIs mediated by unexpected drug-protein interactions [14, 17].

MDS is a clonal hematopoietic disorder characterized by bone marrow failure that can develop into acute myeloid leukemia (AML). MDS progression involves multiple signaling pathways [1, 18]. We found that YSQHP potentially targets the apoptosis, cell cycle, p53, PI3K-AKT, and MAPK pathways in MDS. Transcriptional factor p53 is a tumor suppressor that induces downstream senescence or apoptosis-related genes and is frequently deleted or mutated in human malignancies. MDS patients who harbor TP53 mutations have a significantly higher risk of progressing to AML, compared to those with wild-type alleles [19]. Therefore, the p53 pathway is targeted by multiple anticancer chemotherapeutic drugs [20]. The p53 targets with the highest scores in our analysis were CDK2, EHMT1, EHMT2, KDM1A, and VCP, which usually function as regulators of cell cycle progression [21–23]. EHMTI, EHMT2, and KDM1A, which are histone demethylases, and EHMT1/T2 are targeted in AML to increase hemoglobin F (α2γ2) levels [21]. VCP is a ubiquitous ATPase that is elevated in several tumors, and its inhibition promotes cancer cell death via autophagy [22]. KDM1A-mediated demethylation of the Lys-370 residue of p53 prevents its interaction with BP1, represses downstream transcriptional activation, and stabilizes the DNA methylase, DNMT1. Furthermore, the RCOR/GFI/KDM1A/HDAC complex epigenetically suppresses genes involved in multilineage blood cell development via histone deacetylase (HDAC) recruitment [18, 24]. The YSQHP compounds, indirubin, indigo, tryptophan, G-Rd, G-Rf, and G-Rh2 may bind to KDM1A and increase the expression levels of p53, thereby triggering the apoptosis of malignant cells. Since HDAC1 is a target of arsenic trioxide [25], the latter may also affect the RCOR/GFI/KDM1A/HDAC complex.

![Figure 5: Results of the molecular docking analysis. (Aa-Ea) Overall view of the docking mode of ligands (green) in the receptor binding site (colored ribbons). (Ab-Eb) Site view of potential amino acid residues surrounding ligands (green) in the receptor binding pocket (colored sticks). (Ac-Ec) Two-dimensional interaction map of ligands and receptors. The arrows indicate potential interactions between amino acid residues and ligands. S is the docking score given by MOE software.](image-url)
The molecular docking score of G-Rh2 and CSAP8 was −10.2, indicating that G-Rh2 likely induces CASP8-mediated apoptosis in MDS cells. CASP8 is expressed at low levels in malignant cells, and Xiao-Xi et al. showed that G-Rh2 can promote the apoptosis of CASP8 knockdown tumor cells via a CASP8-independent pathway. In addition, G-Rh2 inhibits the cisplatin-induced apoptosis of normal renal cells by downregulating the CASP8 expression [26]. Therefore, we surmised that G-Rh2 could remove MDS cells and simultaneously protect normal blood cells by targeting CASP8. The casein kinase 2 (CK2) subunits, CSNK2A1, and CSNK2A2 are overexpressed in multiple tumors and mediate the degradation of the PML oncoprotein [27, 28]. CK2 inhibits cancer cell apoptosis by blocking caspase 9 cleavage and CAP8 activation [29]. PRKCA and PRKCB are potentially associated with VEGFA-dependent vascular tube formation [30, 31]. High PRKCA levels in leukemia cells protect the cells from apoptosis via BCL2 activation [32]. Indirubin, indigo, and tryptanthrin may potentially bind to and inhibit PRKCA, PRKCB, PRKCI, LYN, HCK, PIM1, and GS3KB3B expression, thereby restoring normal hematopoietic function. Rh2, Rf, Rd, and Rb1 showed weaker binding than those mentioned above and may play an auxiliary therapeutic role. PRKCI is essential for BCR-ABL oncogene-mediated chemoresistance in leukemia cells and prevents drug-induced apoptosis [33, 34]. YSQHP may affect angiogenesis by regulating PRKCA, PRKCB, and PRKCI levels. The Src family of kinases (SFKs), LYN, and HCK have also been associated with the progression of hematopoietic malignancies. LYN is a negative regulator of hematopoiesis that is aberrantly expressed in AML cells as opposed to normal hematopoietic progenitors. Constitutive activation of LYN in erythroid progenitors leads to major compensatory changes in the erythroid compartment [35, 36]. HCK is overexpressed in Waldenstrom macroglobulinemia (WM) and other hematological malignancies and is targeted by Ibrutinib for the induction of apoptosis in chronic lymphocytic leukemia [37, 38]. PIM1 is aberrantly expressed in several cancers, and its pharmacological inhibition in breast cancer, T-ALL cell lines, adult T-cell leukemia, and T-cell lymphoma (ATL) is therapeutically effective [39, 40]. GSK3β inhibition in nonhuman primate-induced pluripotent stem cells (NHP-iPSCs) promotes the generation of myeloid and lymphoid progenitors [41].

Serine/threonine kinase AKT mediates several pathways that regulate metabolism, proliferation, cell survival, growth, and angiogenesis. The AKT2/P13K pathway is frequently activated in cancer cells and inhibits apoptosis [42]. Given the high levels of activated AKT2 in MDS patients, it is a promising new therapeutic target for MDS and AML [43]. FGFR2 had the highest docking score in our study and was identified as a target of 13 YSQHP compounds. FGFR2, VEGFR2, CSF1R, and EGFR are tyrosine kinases that are constitutively activated in cancer cells to promote tumor progression and angiogenesis. Tyrosine kinase inhibitors (TKIs) are the most commonly used drugs against blood malignancies [44]. CSF1R is expressed in monocytes/macrophages and promotes cell proliferation and differentiation via the PI3K/AKT and MEK/ERK pathways [45]. Monocytes and macrophages are abundant in the marrow of AML patients, and the tumor-associated macrophages (TAMs) are crucial for tumor cell survival and proliferation. Tumor-infiltrating macrophages can be targeted via CSF-1R inhibitors [45, 46]. PTK2B is a member of the FAK family of tyrosine kinases and is activated by BCR-ABL during CML pathogenesis [47]. Taken together, the inhibition of tyrosine kinases may be a mechanism of YSQHP against MDS.

Yisui Qinghuang powder (YSQHP) is a red ginseng-supplemented derivative of Qinghuang powder (QHP) that has been used to treat MDS for over 30 years [9]. YSQHP induces tumor cell apoptosis and promotes stem cell differentiation to replenish peripheral blood cells, which in turn significantly prolongs patient survival [48]. In addition, arsenic trioxide or realgar triggers the cell cycle arrest and apoptosis of tumor cells by activating the p53 pathway and stimulates hematopoiesis by activating dormant stem cells [49, 50]. The major bioactive compounds of indigo naturalis are indirubin, indigo, and tryptanthrin. Indirubin exerts anti-inflammatory and antiapoptotic effects and used for the treatment of hematopathies [11]. The primary ginsenosides in red ginseng are G-Rh1 and G-Rh2, which show weak antitumor activity. In contrast, the rarer ginsenosides, including G-Rh1, G-Rh2, G-Rg2, and G-Rg3, are more potent [51–53]. For instance, G-Rh2 induces the apoptosis of cancer cells by inhibiting FGFR2, CSF1R, EGFR, and LYN [51]. In addition, G-Rg1 may protect hematopoietic stem cells from oxidative damage by inhibiting the GSK3β/Wnt signaling pathway and can reverse lead acetate- (Pb-) induced toxicity by modulating the senescence-associated p53-p21-Rb signaling network [54]. In a recent clinical trial, MDS patients treated with YSQHP showed improved levels of leukocytes, platelets, and hemoglobin after 4 months of treatment after an initial decrease at 2 months [8].

5. Conclusion

CASP8, GSK3B, PRKCA, and VEGFR2 are the potential targets of YSQHP, which potentially inhibits the proliferation of malignant cells and stimulates hematopoietic stem cell differentiation. Furthermore, the antioxidant and anti-senescence activities of red ginseng significantly contribute to the antitumor effects of YSQHP. Our findings should be validated experimentally.

Data Availability

The data used to support the findings of this study are available at the following links: traditional Chinese medicine systems pharmacology (TCMSP) (http://tcmspw.com/tcmsp.php); HerDing (http://210.107.182.73/TCMIDWebService/herdingDemo.jsp) database; STI TCH database (http://stitch.embl.de/); DrugBank database (https://www.drugbank.ca/); PubChem database (https://pubchem.ncbi.nlm.nih.gov/); GeneCards database (https://www.genecards.org/); Online Mendelian Inheritance in Man (OMIM) database (http://www.omim.org/); DAVID (Database Visualization and Integrated Discovery software (http://david.abcc.ncifcrf.gov));
References

[1] Y. Ochi, A. Kon, T. Sakata et al., “Combined cohesin-RUNX1 deficiency synergistically perturbs chromatin looping and causes myelodysplastic syndromes,” Cancer Discovery, vol. 10, no. 6, pp. 836–853, 2020.

[2] J. Chen, Y.-R. Kao, D. Sun et al., “Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level,” Nature Medicine, vol. 25, no. 1, pp. 103–110, 2019.

[3] S. Martinez-Hoyer, Y. Deng, J. Parker et al., “Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome,” Nature Cell Biology, vol. 22, no. 5, pp. 526–533, 2020.

[4] H. E. Ramsey, A. Oganesian, A. E. Gorska et al., “Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model,” Targeted Oncology, vol. 15, no. 2, pp. 231–240, 2020.

[5] R. Mitchell, J. E. Wagner, B. Hirsch, T. E. DeFor, H. Zierhut, and M. L. MacMillan, “Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia,” British Journal of Haematology, vol. 164, no. 3, pp. 384–395, 2014.

[6] Q.-b. Zhou, X.-h. Yang, H.-z. Wang et al., “Effect of Qinghuang powder (青黄散) combined with Bupi yishen decoction (补脾益肾方) in treating patients with refractory cytopenia with multilineage dysplasia through regulating DNA methylation,” Chinese Journal of Integrative Medicine, vol. 25, no. 5, pp. 354–359, 2019.

[7] B. Liu, Z. Song, J. Yu, P. Li, Y. Tang, and J. Ge, “The atherosclerosis-ameliorating effects and molecular mechanisms of BuYangHuanWu decoction,” Biomedicine & Pharmacotherapy, vol. 123, Article ID 109664, 2020.

[8] W. Bai, Research on Factors Affecting Curative Effect of Yisui Qinghuang Powder for Treatment of Myelodysplastic Syndromes, China Academy of Chinese Medical Sciences, Beijing, China, 2011.

[9] H. J. Hu and F. Liu, “Study on the regularity of Yisui Qinghuang powder in the treatment of myelodysplastic syndrome,” Chinese Journal of Woman and Child Health Research, vol. 28, no. S3, pp. 170–171, 2017, [in Chinese].

[10] Y. Huang, Y. Tian, Z. Zhang, and C. Peng, “A HILIC-MS/MS method for the simultaneous determination of seven organic acids in rat urine as biomarkers of exposure to realgar,” Journal of Chromatography B, vol. 905, pp. 37–42, 2012.

[11] H. Li, L. Liu, C. Liu et al., “Deciphering key pharmacological pathways of Qingdai acting on chronic myeloid leukemia using a network pharmacology-based strategy,” Medical Science Monitor, vol. 24, pp. 5668–5688, 2018.

[12] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, p. 13, 2014.

[13] W. Choi, C. H. Choi, Y. R. Kim et al., “HerDing: herb recommendation system to treat diseases using genes and chemicals,” Database (Oxford), vol. 2016, p. baw011, 2016.

[14] H. Luo, P. Zhang, H. Huang et al., “DDI-CPI, a server that predicts drug-drug interactions through implementing the chemical-protein interactome,” Nucleic Acids Research, vol. 42, no. W1, pp. W46–W52, 2014.

[15] D. Szklarczyk, A. Santos, C. von Mering, L. J. Jensen, P. Bork, and M. Kuhn, “Stitch 5: augmenting protein-chemical interaction networks with tissue and affinity data,” Nucleic Acids Research, vol. 44, no. D1, pp. D380–D384, 2016.

[16] D. S. Wishart, C. Knox, A. C. Guo et al., “DrugBank: a knowledgebase for drugs, drug actions and drug targets,” Nucleic Acids Research, vol. 36, no. suppl_1, pp. D901–D906, 2008.

[17] H. Luo, P. Zhang, X. H. Cao et al., “DPDDR-CPI, a server that predicts drug positioning and drug repositioning via chemical-protein interactome,” Scientific Reports, vol. 6, p. 35996, 2016.

[18] B. Reilly, T. N. Tanaka, D. Diep et al., “DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes,” Blood Advances, vol. 3, no. 19, pp. 2845–2858, 2019.

[19] K. Takahashi, K. Patel, C. Bueso-Ramos et al., “Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents,” Oncotarget, vol. 7, no. 12, pp. 14172–14187, 2016.

[20] F. J. Giles, A. T. Stopeck, L. R. Silverman et al., “SU5416, a small molecule tyrosine kinase inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes,” Blood, vol. 102, no. 3, pp. 795–801, 2003.

[21] A. Renneville, P. Van Galen, M. C. Canver et al., “EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression,” Blood, vol. 126, no. 16, pp. 1930–1939, 2015.

[22] P. Magnaghi, R. D’Alessio, B. Valsasina et al., “Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death,” Nature Chemical Biology, vol. 9, no. 9, pp. 548–556, 2013.

[23] M.-H. Delfau-Larue, W. Klapper, F. Berger et al., “High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma,” Blood, vol. 126, no. 5, pp. 604–611, 2015.

[24] J. Huang, R. Sengupta, A. B. Espejo et al., “p53 is regulated by the lysine demethylase LSD1,” Nature, vol. 449, no. 7158, pp. 105–108, 2007.

[25] H.-S. Huang, Z.-M. Liu, and D.-Y. Hong, “Blockage of JNK binding PML,” Nature Chemical Biology, vol. 9, no. 12, pp. 15523–15535, 2012.

[26] X.-X. Guo, Q. Guo, Y. Li, S. Lee, X.-N. Wei, and Y.-H. Jin, “Ginsenoside Rh2 induces human hematoma cell apoptosis via bax/bak triggered cytochrome c release and caspase-9/caspase-8 activation,” International Journal of Molecular Sciences, vol. 13, no. 12, pp. 15523–15535, 2012.

[27] X. W. Zhang, X. J. Yan, Z. R. Zhou et al., “Arsenic trioxide induces apoptosis in myelodysplastic syndromes,” Toxiconology and Applied Pharmacology, vol. 244, no. 2, pp. 234–241, 2010.

[28] P. P. Scaglioni, T. M. Yung, L. F. Cai et al., “ACK2-dependent clinicopathological and biological implications of TP53 mutations in myelodysplastic syndromes,” Scientific Reports, vol. 6, no. 1, pp. 247–258, 2002.

[29] Y. Li, E.-C. Müller, A. Otto, R. Dietz, and R. von Harssdorf, “Phosphorylation by protein kinase CK2,” Molecular Cell, vol. 10, no. 2, pp. 247–258, 2002.
[30] C. Moncada de la Rosa, A. Radziwon-Balicka, H. El-Sikhry et al., "Pharmacologic protein kinase C inhibition uncouples human platelet-stimulated angiogenesis from collagen-induced aggregation," *Journal of Pharmacology and Experimental Therapeutics*, vol. 345, no. 1, pp. 15–24, 2013.

[31] H. Xu, P. Czerwinski, M. Hortmann, H.-Y. Sohn, U. Forstermann, and H. Li, "Protein kinase C promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor," *Cardiovascular Research*, vol. 78, no. 2, pp. 349–355, 2008.

[32] T. Jiffar, S. Kurinna, G. Suck et al., "PKC α mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation," *Leukemia*, vol. 18, no. 3, pp. 505–512, 2004.

[33] R. M. Baldwin, M. Garrant-Lalone, D. A. E. Parolin, P. M. Krzyzanowski, M. A. Andrade, and I. A. J. Lorimer, "Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Cζ-mediated attenuation of p38 MAP kinase signaling," *Oncogene*, vol. 25, no. 20, pp. 2909–2919, 2006.

[34] C. Dos Santos, C. Demur, V. Bardet, N. Prade-Houdellier, B. Payrastre, and C. Récher, "A critical role for Lyn in acute myeloid leukemia," *Blood*, vol. 111, no. 4, pp. 2269–2279, 2008.

[35] M. Seetharam, A. C. Fan, M. Tran et al., "Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na," *Leukemia Research*, vol. 36, no. 1, pp. 98–103, 2012.

[36] J. Cortes, E. Jabbour, H. Kantarjian et al., "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors," *Blood*, vol. 110, no. 12, pp. 4005–4011, 2007.

[37] D. K. Edwards, K. Watanabe-Smith, A. Rofelty et al., "CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells," *Blood*, vol. 133, no. 6, pp. 588–599, 2019.

[38] L. Bencheikh, M. K. Diop, J. Riviere et al., "Dynamic gene regulation by nuclear colony-stimulating factor 1 receptor in human monocytes and macrophages," *Nature Communications*, vol. 10, no. 1, p. 1935, 2019.

[39] F. Albano, A. Zagaria, L. Anelli et al., "Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation," *Molecular Cancer*, vol. 12, no. 1, p. 36, 2013.

[40] Z. Qi, W. Li, J. Tan et al., "Effect of ginsenoside Rh2 on renal apoptosis in cisplatin-induced nephrotoxicity in vivo," *Phytomedicine*, vol. 61, Article ID 152862, 2019.

[41] M. Bellon, L. Lu, and C. Nicot, "Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia," *Blood*, vol. 127, no. 20, pp. 2439–2450, 2016.

[42] S. Zhang, J. Zhang, X. Dong, and X. Sun, "Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status," *Molecular Biology Reports*, vol. 35, no. 3, pp. 421–429, 2008.

[43] J.-M. Ramirez, O. Schaad, S. Durual et al., "Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts," *British Journal of Haematology*, vol. 144, no. 2, pp. 251–262, 2009.

[44] Z. Cheng, M. Zhang, C. Ling et al., "Neuroprotective effects of ginsenosides against cerebral ischemia," *Molecules*, vol. 24, no. 6, 2019.

[45] H. Yan, H. Jin, Y. Fu, Z. Yin, and C. Yin, "Production of rare ginsenosides Rg3 and Rh2 by endophytic bacteria from panax ginseng," *Journal of Agricultural and Food Chemistry*, vol. 67, no. 3, pp. 8493–8499, 2019.

[46] J. Li, D. Cai, X. Yao et al., "Protective effect of ginsenoside Rg1 on hematopoietic stem/progenitor cells through attenuating oxidative stress and the wnt/beta-catenin signaling pathway in a mouse model of d-Galactose-induced aging," *International Journal of Molecular Sciences*, vol. 17, no. 6, 2016.

[47] J. C. Ghosh, M. D. Siegelin, V. Vaira et al., "Adaptive migration of CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene," *Blood*, vol. 127, no. 25, pp. 3237–3252, 2016.

[48] A. R. Poh, C. G. Love, F. Masson et al., "Inhibition of hematopoietic cell kinase activity suppresses myeloid cell-mediated colon cancer progression," *Cancer Cell*, vol. 31, no. 4, pp. 563–575.e5, 2017.

[49] M. Bellon, L. Lu, and C. Nicot, "Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia," *Blood*, vol. 127, no. 20, pp. 2439–2450, 2016.

[50] F. Albano, A. Zagaria, L. Anelli et al., "Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation," *Molecular Cancer*, vol. 12, no. 1, p. 36, 2013.